[go: up one dir, main page]

DK0832094T3 - Aminosterolforbindelser, som er nyttige som inhibitorer for natrium/proton-omskifteren (NHE), farmaceutiske fremgangsmåder og sammensætninger, som anvender sådanne inhibitorer, og fremgangsmåder til vurdering af den NHE-inhiberende effektivitet af for.. - Google Patents

Aminosterolforbindelser, som er nyttige som inhibitorer for natrium/proton-omskifteren (NHE), farmaceutiske fremgangsmåder og sammensætninger, som anvender sådanne inhibitorer, og fremgangsmåder til vurdering af den NHE-inhiberende effektivitet af for..

Info

Publication number
DK0832094T3
DK0832094T3 DK96922490T DK96922490T DK0832094T3 DK 0832094 T3 DK0832094 T3 DK 0832094T3 DK 96922490 T DK96922490 T DK 96922490T DK 96922490 T DK96922490 T DK 96922490T DK 0832094 T3 DK0832094 T3 DK 0832094T3
Authority
DK
Denmark
Prior art keywords
inhibitors
nhe
methods
sodium
useful
Prior art date
Application number
DK96922490T
Other languages
Danish (da)
English (en)
Inventor
Michael Zasloff
Ann Shinnar
William A Kinney
Jon Williams
Meena N Rao
Mark Anderson
Michael Mclane
Steven Jones
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/479,457 external-priority patent/US5763430A/en
Priority claimed from US08/483,057 external-priority patent/US5795885A/en
Priority claimed from US08/475,572 external-priority patent/US5840936A/en
Priority claimed from US08/476,855 external-priority patent/US5874597A/en
Priority claimed from US08/479,455 external-priority patent/US5994336A/en
Priority claimed from US08/483,059 external-priority patent/US5840740A/en
Priority claimed from US08/487,443 external-priority patent/US5847172A/en
Application filed by Genaera Corp filed Critical Genaera Corp
Application granted granted Critical
Publication of DK0832094T3 publication Critical patent/DK0832094T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
DK96922490T 1995-06-07 1996-06-07 Aminosterolforbindelser, som er nyttige som inhibitorer for natrium/proton-omskifteren (NHE), farmaceutiske fremgangsmåder og sammensætninger, som anvender sådanne inhibitorer, og fremgangsmåder til vurdering af den NHE-inhiberende effektivitet af for.. DK0832094T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US08/479,457 US5763430A (en) 1995-06-07 1995-06-07 Method of treating a viral infection by administering a steroid compound
US08/483,057 US5795885A (en) 1995-06-07 1995-06-07 Method of inhibiting profileration of cells by administering an aminosterol compound
US08/475,572 US5840936A (en) 1995-06-07 1995-06-07 Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US08/476,855 US5874597A (en) 1995-06-07 1995-06-07 Certain aminosterol compounds and pharmaceutical compositions including these compounds
US08/479,455 US5994336A (en) 1995-06-07 1995-06-07 Method of inhibiting proliferation of cells by administering an aminosterol compound
US08/483,059 US5840740A (en) 1995-06-07 1995-06-07 Aminosterol compounds and a method of treating infection using the aminosterol compounds
US08/487,443 US5847172A (en) 1995-06-07 1995-06-07 Certain aminosterol compounds and pharmaceutical compositions including these compounds

Publications (1)

Publication Number Publication Date
DK0832094T3 true DK0832094T3 (da) 2004-05-17

Family

ID=27569803

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96922490T DK0832094T3 (da) 1995-06-07 1996-06-07 Aminosterolforbindelser, som er nyttige som inhibitorer for natrium/proton-omskifteren (NHE), farmaceutiske fremgangsmåder og sammensætninger, som anvender sådanne inhibitorer, og fremgangsmåder til vurdering af den NHE-inhiberende effektivitet af for..

Country Status (10)

Country Link
EP (2) EP0832094B1 (fr)
JP (2) JP4104164B2 (fr)
AT (1) ATE259375T1 (fr)
AU (1) AU723663C (fr)
CA (1) CA2223910C (fr)
DE (1) DE69631527T2 (fr)
DK (1) DK0832094T3 (fr)
ES (1) ES2216049T3 (fr)
PT (1) PT832094E (fr)
WO (1) WO1996040728A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
PT910382E (pt) * 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
CA2255856C (fr) * 1996-05-17 2008-05-13 Magainin Pharmaceuticals Inc. Utilisations therapeutiques d'un compose d'aminosterol
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
WO1998019682A1 (fr) * 1996-11-01 1998-05-14 Magainin Pharmaceuticals Inc. Certains composes aminosterols et leur utilisation
US6262283B1 (en) * 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
DK1274718T3 (da) 2000-04-12 2007-02-12 Genaera Corp En fremgangsmåde til forberedelse af 7.alpha.-hydroxy 3-aminosubstituerede steroler vee en ubeskyttet 7.alpha.-hydroxy gruppe
WO2006119211A2 (fr) * 2005-05-02 2006-11-09 Genaera Corporation Procedes et compositions pour traiter des troubles oculaires
EP2051716A1 (fr) * 2006-04-21 2009-04-29 Genaera Corporation Induction de perte de poids et inhibition sélective de ptp1b
WO2009032321A2 (fr) * 2007-09-06 2009-03-12 Genaera Corporation Procédé de traitement du diabète
US20110060051A1 (en) 2008-05-09 2011-03-10 Merck Patent Gesellschaft Mit Beschrankter Haftung Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction
PL2758060T3 (pl) 2011-09-19 2018-04-30 ETH Zürich Modulatory ROR-gamma do leczenia powikłań cukrzycy typu II
CA2870671C (fr) 2012-04-20 2020-05-12 Ohr Pharmaceutical Inc. Aminosteroides pour le traitement d'une maladie associee a ptp1b
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
JP6518230B2 (ja) 2013-03-15 2019-05-22 ブリガム・ヤング・ユニバーシティＢｒｉｇｈａｍ Ｙｏｕｎｇ Ｕｎｉｖｅｒｓｉｔｙ 炎症、自己免疫疾患、および疼痛を治療する方法
EP2781217A1 (fr) * 2013-03-18 2014-09-24 ETH Zurich Modulateurs de la gamma ROR
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
US10441595B2 (en) * 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
FR3033563B1 (fr) * 2015-03-12 2018-04-13 Virbac Composes analogues de la squalamine utiles comme agents antibacteriens
FR3055801B1 (fr) * 2016-09-15 2020-10-30 Virbac Derives esters de squalamine pour le traitement des infections
WO2019050903A1 (fr) * 2017-09-08 2019-03-14 Enterin Laboratories, Inc. Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
WO2020028810A1 (fr) * 2018-08-03 2020-02-06 Enterin Laboratories Compositions et méthodes pour traiter des troubles de l'axe intestin-cerveau
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth
CN114929724B (zh) * 2019-08-02 2024-12-10 因特尔公司 氨基固醇ent-03化合物、包含其的相关组合物以及其使用方法
WO2021025974A1 (fr) * 2019-08-02 2021-02-11 Enterin, Inc. Dérivés de squalamine humaine, compositions associées les comprenant, et procédés d'utilisation correspondants
CN112782300B (zh) * 2020-12-25 2022-04-12 山东省食品药品检验研究院 一种胆烷酸的同分异构体及其检测方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) * 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
WO1994019366A1 (fr) * 1993-02-26 1994-09-01 Magainin Pharmaceuticals Inc. Synthese chimique de la squalamine
DE69412596T2 (de) * 1993-03-10 1999-03-04 Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel

Also Published As

Publication number Publication date
DE69631527T2 (de) 2004-09-23
WO1996040728A2 (fr) 1996-12-19
EP1420027A2 (fr) 2004-05-19
CA2223910A1 (fr) 1996-12-19
WO1996040728A3 (fr) 1997-03-27
ES2216049T3 (es) 2004-10-16
PT832094E (pt) 2004-06-30
EP0832094A2 (fr) 1998-04-01
JP4104164B2 (ja) 2008-06-18
DE69631527D1 (de) 2004-03-18
AU723663C (en) 2001-11-01
AU723663B2 (en) 2000-08-31
ATE259375T1 (de) 2004-02-15
JP2002515019A (ja) 2002-05-21
EP0832094B1 (fr) 2004-02-11
JP2007314577A (ja) 2007-12-06
AU6334996A (en) 1996-12-30
EP1420027A3 (fr) 2012-01-04
CA2223910C (fr) 2008-09-16

Similar Documents

Publication Publication Date Title
DK0832094T3 (da) Aminosterolforbindelser, som er nyttige som inhibitorer for natrium/proton-omskifteren (NHE), farmaceutiske fremgangsmåder og sammensætninger, som anvender sådanne inhibitorer, og fremgangsmåder til vurdering af den NHE-inhiberende effektivitet af for..
ZA964819B (en) Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds.
ES2167905T3 (es) Composiciones herbicidas.
NO942064L (no) yminhibitorer
DK0785770T3 (da) Sammensætninger til bekæmpelse af hæmorroider og fremgangsmåde til anvendelse deraf
DE69531403D1 (de) Allosterische modulatoren des nmda-rezeptors
ES2193252T3 (es) Quinolonas y su uso terapeutico.
NO961664L (no) Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som anti-diabetiske midler
DK0873295T3 (da) Dimer-selektive RXR-modulatorer og fremgangsmåder til deres anvendelse
AR013746A1 (es) Sustitucion bioisosterica de catecol por indazol en compuesto terapeuticos activos
ZA964818B (en) Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds.
BR9607560A (pt) Composições cométicas anidras contendo agentes dermatologicamente ativo
ATE168682T1 (de) Herbizide substituierte 1-phenyl-oder 1-pyridinyl-benzotriazole
NO983530L (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
DK0658585T3 (da) Amidinophenylalaninderivater, fremgangsmåde til deres fremstilling, deres anvendelse og midler indeholdende disse som antik
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
NO943765L (no) Aryloksybenzen-herbicidmidler
NO995676D0 (no) Isoftalamid derivat som gul polymorf
CO4761036A1 (es) Mezclas fungicidas
NO20003766D0 (no) PAI-2 og t-PA som diagnostiske markører for periodontale sykdommer
DK1104419T3 (da) N-substituerede azabicyloheptan-derivater, deres fremstilling og anvendelse
DK1105388T3 (da) N-substituerede azabicycloheptan-derivater, fremstilling og anvendelse heraf
DK0594940T3 (da) N-Oxy- og thioalkylcarbonyloxyalkylpyrroler som insekticide, acaricide og molluskicide midler
DK0877730T3 (da) Arylacrylforbindelser til anvendelse som fungicider
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.